Invivoplus mouse igg2a isotype control

To deplete NK cells, mice were i.p. injected with 300 μg of anti-NK1.1 depleting Ab (PK136, Bio X Cell) or InVivoPlus mouse IgG2a isotype control (Bio X Cell) 1 day prior to and following PO inoculation of reovirus. NK cell depletion was assessed using flow cytometry of single-cell suspensions of blood, spleen, and MLNs at 2 dpi and MLNs at 3 dpi following staining with the NK cell-specific markers NK1.1 and DX5 following manufacturer’s recommendations. To deplete IL-12, mice were i.p. injected with 750 μg of anti–IL-12p40 depleting Ab (C17.8, Bio X Cell) or InVivoPlus mouse IgG2a isotype control (Bio X Cell) following previously established protocols (65 (link)–67 (link)).

To deplete CD4⁺ T cells, mice received intraperitoneal injections of 500 μg of anti-CD4 mAb GK1.5 or InVivoPlus Mouse IgG2b Isotype control (Bio X Cell) twice a week for 4 weeks, starting from 4 weeks p.i. For the depletion of B cells, mice received intraperitoneal injections of 250 μg rituximab (anti-CD20 mAb) (a gift from Genentech) or InVivoPlus Mouse IgG2a Isotype control (Bio X Cell) twice a week. Anti-CD20 mAb injections were administered either on day 1 p.i. or starting from week 12 p.i. to analyze mLNs at weeks 3 and 16 p.i., respectively.